StockData
Rein Therapeutics, Inc. logo

Rein Therapeutics, Inc. (RNTX) stock

RNTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$0.36−0.04 (-10.90%)

Close on Nov 17, 2026Market cap $30.75MP/E –Yield 0.00%

Rein Therapeutics cash

Cash and short-term investments held at the end of each period.

Rein Therapeutics's cash was $43.63M at Jun 30, 2026. For fiscal 2025 it was $3.22M, down 75.0% from the year before. Over ten years it grew -1.6% a year on average. The highest annual figure on record is $50.75M in fiscal 2017.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$3.22M-75.0%
FY2024Dec 31, 2024$12.87M-25.8%
FY2023Dec 31, 2023$17.34M-18.4%
FY2022Dec 31, 2022$21.24M-53.8%
FY2021Dec 31, 2021$45.93M+232.7%
FY2020Dec 31, 2020$13.81M-24.5%
FY2019Dec 31, 2019$18.28M-11.7%
FY2018Dec 31, 2018$20.70M-59.2%
FY2017Dec 31, 2017$50.75M+144.0%
FY2016Dec 31, 2016$20.80M+452.1%
FY2015Dec 31, 2015$3.77M-39.3%
FY2014Dec 31, 2014$6.21M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$43.63M+662.4%
Q1 FY2026Mar 31, 2026$4.45M-40.2%
Q4 FY2025Dec 31, 2025$3.22M-75.0%
Q3 FY2025Sep 30, 2025$4.05M-77.1%
Q2 FY2025Jun 30, 2025$5.72M-73.9%
Q1 FY2025Mar 31, 2025$7.43M-38.3%
Q4 FY2024Dec 31, 2024$12.87M-25.8%
Q3 FY2024Sep 30, 2024$17.65M+46.3%
Q2 FY2024Jun 30, 2024$21.92M+60.4%
Q1 FY2024Mar 31, 2024$12.04M-28.0%
Q4 FY2023Dec 31, 2023$17.34M-18.4%
Q3 FY2023Sep 30, 2023$12.07M-52.6%
Q2 FY2023Jun 30, 2023$13.67M-57.8%
Q1 FY2023Mar 31, 2023$16.72M-56.1%
Q4 FY2022Dec 31, 2022$21.24M-53.8%
Q3 FY2022Sep 30, 2022$25.48M-51.2%
Q2 FY2022Jun 30, 2022$32.38M-45.6%
Q1 FY2022Mar 31, 2022$38.08M-39.9%
Q4 FY2021Dec 31, 2021$45.93M+232.7%
Q3 FY2021Sep 30, 2021$52.23M+269.9%
Q2 FY2021Jun 30, 2021$59.48M+215.0%
Q1 FY2021Mar 31, 2021$63.35M+399.0%
Q4 FY2020Dec 31, 2020$13.81M-24.5%
Q3 FY2020Sep 30, 2020$14.12M-42.5%
Q2 FY2020Jun 30, 2020$18.88M-40.1%
Q1 FY2020Mar 31, 2020$12.70M-4.3%
Q4 FY2019Dec 31, 2019$18.28M-11.7%
Q3 FY2019Sep 30, 2019$24.56M-12.1%
Q2 FY2019Jun 30, 2019$31.52M-11.9%
Q1 FY2019Mar 31, 2019$13.27M-69.3%
Q4 FY2018Dec 31, 2018$20.70M-59.2%
Q3 FY2018Sep 30, 2018$27.95M-50.9%
Q2 FY2018Jun 30, 2018$35.79M+215.5%
Q1 FY2018Mar 31, 2018$43.29M+433.3%
Q4 FY2017Dec 31, 2017$50.75M+144.0%
Q3 FY2017Sep 30, 2017$56.87M+1162.5%
Q2 FY2017Jun 30, 2017$11.34M–
Q1 FY2017Mar 31, 2017$8.12M–
Q4 FY2016Dec 31, 2016$20.80M–
Q3 FY2016Sep 30, 2016$4.50M–

More Rein Therapeutics figures

See a number that looks wrong?